Literature DB >> 11571300

Tumor necrosis factor-alpha-converting enzyme mediates the inducible cleavage of fractalkine.

C L Tsou1, C A Haskell, I F Charo.   

Abstract

Fractalkine (FK, CX3CL1) is a novel multidomain protein expressed on the surface of endothelial cells. As a full-length transmembrane protein, FK binds cells expressing CX3CR1, its cognate receptor, with high affinity. Proteolytic cleavage of FK releases a soluble form that is a potent chemoattractant for monocytes, T cells, and natural killer cells. Activation of protein kinase C dramatically increases the rate of this cleavage. Regulation of FK cleavage is critical for maintaining the balance between the immobilized and soluble forms, but the protease responsible has not been identified. Here we report that tumor necrosis factor-alpha-converting enzyme (TACE) is primarily responsible for the inducible cleavage of FK. After transfection into host cells, the proteolytic cleavage of FK was blocked by TACE-specific inhibitors and was not detected in cells genetically altered to remove TACE activity. In contrast, the constitutive cleavage of FK was not mediated by TACE and proceeded normally in TACE-null fibroblasts. We conclude that TACE is primarily responsible for the inducible cleavage of FK. These studies identify a potentially important link between local generation of potent cytokines and control of the balance between the cell adhesion and chemotactic properties of FK.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11571300     DOI: 10.1074/jbc.M107327200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  60 in total

1.  CX3CR1+ lung mononuclear phagocytes spatially confined to the interstitium produce TNF-α and IL-6 and promote cigarette smoke-induced emphysema.

Authors:  Zeyu Xiong; Adriana S Leme; Prabir Ray; Steven D Shapiro; Janet S Lee
Journal:  J Immunol       Date:  2011-01-28       Impact factor: 5.422

2.  The fractalkine receptor CX3CR1 is a key mediator of atherogenesis.

Authors:  Myron I Cybulsky; Robert A Hegele
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

3.  Neuron-Microglia Dialogue and Hippocampal Neurogenesis in the Aged Brain.

Authors:  Carmelina Gemma; Adam D Bachstetter; Paula C Bickford
Journal:  Aging Dis       Date:  2010-12-01       Impact factor: 6.745

4.  In vivo structure/function and expression analysis of the CX3C chemokine fractalkine.

Authors:  Ki-Wook Kim; Alexandra Vallon-Eberhard; Ehud Zigmond; Julia Farache; Elias Shezen; Guy Shakhar; Andreas Ludwig; Sergio A Lira; Steffen Jung
Journal:  Blood       Date:  2011-09-27       Impact factor: 22.113

Review 5.  Microglia in Health and Disease.

Authors:  Richard M Ransohoff; Joseph El Khoury
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-09-09       Impact factor: 10.005

6.  Fractalkine-induced MFG-E8 leads to enhanced apoptotic cell clearance by macrophages.

Authors:  Michael Miksa; Dhruv Amin; Rongqian Wu; Thanjavur S Ravikumar; Ping Wang
Journal:  Mol Med       Date:  2007 Nov-Dec       Impact factor: 6.354

Review 7.  Chemokines: integrators of pain and inflammation.

Authors:  Fletcher A White; Sonia K Bhangoo; Richard J Miller
Journal:  Nat Rev Drug Discov       Date:  2005-10       Impact factor: 84.694

Review 8.  Osteoarthritis joint pain: the cytokine connection.

Authors:  Rachel E Miller; Richard J Miller; Anne-Marie Malfait
Journal:  Cytokine       Date:  2014-07-24       Impact factor: 3.861

9.  Tissue-specific differential antitumour effect of molecular forms of fractalkine in a mouse model of metastatic colon cancer.

Authors:  S Vitale; B Cambien; B F Karimdjee; R Barthel; P Staccini; C Luci; V Breittmayer; F Anjuère; A Schmid-Alliana; H Schmid-Antomarchi
Journal:  Gut       Date:  2006-07-26       Impact factor: 23.059

10.  The spectrum of resistance in SR/CR mice: the critical role of chemoattraction in the cancer/leukocyte interaction.

Authors:  Gregory Riedlinger; Jonathan Adams; John R Stehle; Michael J Blanks; Anne M Sanders; Amy M Hicks; Mark C Willingham; Zheng Cui
Journal:  BMC Cancer       Date:  2010-05-03       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.